TFAP2B and breast carcinoma: In HCC, slow-growing luminal breast cancer, and cervical cancer, TFAP2B inhibits EMT and Wnt/β-catenin signaling to limit tumor growth and migration, which may be related to the Slug and Snail signaling pathways and loss of E-cadherin and low Ki67 [54–56].